Form 4: MaxCyte Director John Johnston Exercises Options and Sells Shares Under 10b5-1 Plan

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 26, 2024, John Johnston, a director of MaxCyte, Inc., exercised stock options to acquire 3,000 shares of common stock at a price of $2.926 per share.
• Simultaneously, Johnston sold 3,000 shares of MaxCyte common stock at a weighted average price of $4.746 per share, with individual sales prices ranging from $4.63 to $4.79.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 19, 2023.
• Following these transactions, Johnston directly owns 141,950 shares of MaxCyte common stock and 10,396 stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were part of a pre-planned trading strategy and do not necessarily indicate a change in the director's confidence in the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a lack of insider information influencing the trades.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge insider sentiment and potential future stock performance.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider trading.

Key Dates